瑞士制药巨头罗氏（Roche）4月9日表示研究证明该公司的抗丙肝药物Pegasys能有效促进乙肝的治疗
SYDNEY -(Dow Jones)- Swiss pharmaceutical company Roche Holding AG said Wednesday a new study found that its hepatitis C drug Pegasys also more than doubled the efficacy of conventional treatments of chronic hepatitis B.
Study results presented April 9 at the 11th International Symposium on Viral Hepatitis and Liver Disease, in Sydney demonstrate that PEGASYS, a new generation hepatitis C therapy, more than doubled the efficacy of conventional interferon in the treatment of chronic hepatitis B (CHB).
The Phase II study assessed the efficacy of PEGASYS in patients with difficult-to-treat HBeAg-positive CHB, which was defined as high pre-treatment HBV DNA (high levels of replicating virus in the patient's liver) and low pre- treatment ALT (indicating a weak natural response from the patients immune system to HBV).
These factors are considered predictors of a poor response to HBV therapy. As in hepatitis C, where genotype 1 is considered difficult to treat, there is also evidence that those infected by the HBV genotype C virus respond less well to treatment.
"Until now, there was only a slim chance that these hepatitis B patients could be cured of their disease," said Professor Graham Cooksley, the lead investigator of the study and Senior Principal Research Fellow, Clinical Research Centre, Royal Brisbane Hospital, Australia.
"These monotherapy results are extremely positive and demonstrate the same kind of efficacy in hepatitis B as we saw with genotype 1 patients in hepatitis C. PEGASYS works very well in those with the most treatment-resistant disease."
Company Web Site: http://www.roche.com 【发表/查看评论】  【 打印本页】 【关闭窗口】
|
